Intro

The chapter highlights the impact of Nvidia's stock price decline on the market and speculates on the reasons behind it. It also discusses Novo Nordisk's significant investment in a new factory to cater to the demand for weight loss and diabetes drugs, along with recent developments with their drug approval and patent disputes.